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Abstract
Chemokines and their receptors are involved in the development and cancer progression. The chemokine CXCL12 interacts
with its receptor, CXCR4, to promote cellular adhesion, survival, proliferation and migration. The CXCR4 gene is upregulated
in several types of cancers, including skin, lung, pancreas, brain and breast tumors. In pancreatic cancer and melanoma,
CXCR4 expression is regulated by DNA methylation within its promoter region. In this study we examined the role of
cytosine methylation in the regulation of CXCR4 expression in breast cancer cell lines and also correlated the methylation
pattern with the clinicopathological aspects of sixty-nine primary breast tumors from a cohort of Brazilian women. RT-PCR
showed that the PMC-42, MCF7 and MDA-MB-436 breast tumor cell lines expressed high levels of CXCR4. Conversely, the
MDA-MB-435 cell line only expressed CXCR4 after treatment with 5-Aza-CdR, which suggests that CXCR4 expression is
regulated by DNA methylation. To confirm this hypothesis, a 184 bp fragment of the CXCR4 gene promoter region was
cloned after sodium bisulfite DNA treatment. Sequencing data showed that cell lines that expressed CXCR4 had only 15% of
methylated CpG dinucleotides, while the cell line that not have CXCR4 expression, had a high density of methylation (91%).
Loss of DNA methylation in the CXCR4 promoter was detected in 67% of the breast cancer analyzed. The absence of CXCR4
methylation was associated with the tumor stage, size, histological grade, lymph node status, ESR1 methylation and CXCL12
methylation, metastasis and patient death. Kaplan-Meier curves demonstrated that patients with an unmethylated CXCR4
promoter had a poorer overall survival and disease-free survival. Furthermore, patients with both CXCL12 methylation and
unmethylated CXCR4 had a shorter overall survival and disease-free survival. These findings suggest that the DNA
methylation status of both CXCR4 and CXCL12 genes could be used as a biomarker for prognosis in breast cancer.
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Introduction
Breast cancer is a major public health issue worldwide. In 2004,
the most recent year available for global data, there were 1.15
million new breast cancer cases and over 500,000 deaths reported
worldwide [1]. Although advances have been made in reducing
the mortality rates and improving survival, cancer is still the
leading cause of death among men and women under 85 years of
age in the United States [2]. In Brazil, 49,420 new cases of breast
cancer have been estimated to occur between 2010 and 2011 [3].
Data from the Unique System of Heath (SUS) demonstrated that
the mortality rates for breast cancer are 12.6 out of every 100,000
cases in Brazilian women (http://mortalidade.inca.gov.br). Me-
tastases cause 90% of human cancer deaths [4]. For breast cancer,
due to the inability to accurately predict the risk of metastasis,
more than 80% of patients receive adjuvant chemotherapy.
However, approximately 40% of these patients still relapse and die
of metastatic breast cancer within five years [4].
Generally, cancer is described as a disease driven by progressive
genetic abnormalities involving mutations in oncogenes and tumor
suppressor genes as well as other chromosomal aberrations [5].
Breast cancer, similar to other types of cancer, is driven by
epigenetic alterations, which do not affect the primary DNA
sequence [6,7,8]. These alterations lead to aberrant transcriptional
regulation, which results in changes in the expression pattern of
genes implicated in many cellular functions. These epigenetic
alterations include changes in DNA methylation and histone
modifications [7]. DNA hypermethylation is frequently associated
with gene repression and genomic instability through silencing of
the DNA repair genes, and several genes have been shown to be
silenced in different steps of breast cancer [9,10].
Although the list of hypermethylated genes involved in the
tumorigenesis of breast cancer has increased, much of the focus
has remained on the estrogen receptor alpha (ESR1) and
progesterone receptor (PGR) as these proteins have been
implicated in breast cancer development and progression [7].
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1These genes are viable prognostic markers, and approximately
70% of patients are suitable candidates for endocrine therapy [11].
The HER2 protein, which is present in approximately 30% of
patients, serves as another important molecular prognosis marker
for breast cancer and makes tumors suitable for herceptin
antibody treatment [12]. However, despite the existence of well-
documented molecular markers, breast cancer deaths remain a
major public health issue.
Understanding the molecular mechanisms involved in breast
cancer initiation and progression could provide strategies to
identify new diagnostic and prognostic markers as well as better
treatment for the disease. Thus, we evaluated the expression
pattern and methylation status of the CXCR4 gene, which encodes
a well-known protein involved in breast cancer. The CXCR4
chemokine together with its ligand, CXCL12, are involved in the
mechanism of breast cancer metastasis. Breast cancer cells from
primary tumors over-expressing CXCR4 are attracted to
CXCL12 expressing cells in the lung, lymph nodes, liver or
bones, which leads to the metastasis of detached tumor cells [13].
Immunohistochemical analyses have shown that specific patterns
of CXCR4 expression (i.e., in the nucleus or cytoplasm) are
correlated with a high nuclear grade [14] or lymph node
metastasis [15,16]. Recent studies have indicated that the
epigenetic mechanisms that negatively regulate the expression of
CXCL12 and ESR1 are involved in breast cancer metastasis and
correlate with poor survival of patients [17]. Additionally, in
melanoma and pancreatic cancer, the CXCR4 promoter is
regulated by increased DNA methylation, which results in lower
CXCR4 mRNA expression [18,19].
In this study, we evaluated the methylation pattern of the
CXCR4 gene promoter in breast tumor cell lines and primary
tumor samples and correlated this pattern with clinicopathological
data. We also compared the results from the CXCR4 DNA
methylation study with the results from our previous CXCL12
study [17]. Together, these results suggest that the epigenetic
regulation by DNA methylation of both the CXCR4 and CXCL12
genes in breast cancer could serve as a potential biomarker to
indicate patient prognosis.
Results
CXCR4 expression in breast tumor cell lines
The expression pattern of CXCR4 in four breast tumor cell lines
was evaluated using RT-PCR. A 389 bp transcript corresponding
to the CXCR4 gene was detected in the PMC-42, MCF-7 and
MDA-MB-436 cell lines (Fig. 1A). In contrast, CXCR4 expression
was not detected in the MDA-MB-435 cell line. To determine if
CXCR4 expression was lost, all analyses were repeated at least
twice. GAPDH expression was detected in all samples tested
(Fig. 1A).
To confirm the epigenetic transcriptional silencing of CXCR4 in
breast cancer, we treated the MDA-MB-435 cell line with the
demethylating agent 5-aza-29-deoxycytidine (5-aza-CdR). As
previously demonstrated in pancreatic and melanoma cell lines,
the expression of CXCR4 was restored in the MDA-MB-435 cells
upon 5-aza-CdR treatment (Fig. 1B) [18,19].
CXCR4 silencing by DNA methylation
Sato et al. (2005) [18] analyzed four DNA areas within the 59
upstream region of the CXCR4 gene using a combined bisulfite
restriction analysis (COBRA) method. Their work demonstrated
that CXCR4 is regulated by DNA methylation in human
pancreatic cancer cell lines within the TSS region, which contains
the majority of the methylated CpG dinucleotides. In our work, we
therefore selected the TSS region, comprised of nucleotides from
the positions 2173 to +11 in the CXCR4 promoter, to analyze in
our breast tumor cell lines and tumor samples.
Sodium bisulfite sequencing was performed on 184 bp DNA
fragment containing 19 CpG dinucleotides. The methylation
patterns of eight independent CXCR4 alleles in the PMC-42,
Figure 1. CXCR4 expression analysis using semi-quantitative RT-PCR in breast cancer tumor cell lines and CXCR4 expression after 5-
aza-29-deoxycytidine (D-Aza) treatment. (A) The bands represent CXCR4 expression in the PMC-42, MCF7, MDA-MB-436 cell lines and (B) MDA-
MB-435 mock or MDA-MB-435 D-Aza represent the MDA-MB-435 cell line before and after treatment with 5-aza-29-deoxycytidine, respectively. The
GAPDH gene was used as a positive control in both experiments. MW, Molecular Weight, NC represents the PCR reaction without DNA (negative
control).
doi:10.1371/journal.pone.0029461.g001
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analyzed. The CXCR4-negative cell line, MDA-MB-435, demon-
strated a hypermethylation of 91% of the CpG dinucleotides
(Fig. 2). The high density of cytosine methylation explains the
inactivation of CXCR4 in the MDA-MB-435 cell line, which was
demonstrated by RT-PCR (Fig. 1A). This inactivation due to
hypermethylation was confirmed by treatment with 5-aza-29-
deoxycytidine, a demethylating agent, which resulted in the
subsequent expression of CXCR4 (Fig. 1B). In contrast, the cell
lines that expressed CXCR4, which were PMC-42, MCF-7 and
MDA-MB-436, had lower levels of CpG dinucleotide methylation
(i.e., 17%, 20% and 9%, respectively) (Fig. 2). The presence of a
greater number of unmethylated CpG dinucleotides may explain
the expression of the CXCR4 gene in these cell lines, which was
verified by RT-PCR (Fig. 1A).
The methylation profile comparing the CXCR4-expressing cell
lines (MCF7, PMC-42 and MDA-MB-436) to the non-expressing
cell line (MDA-MB-435) demonstrated that the differentially
methylated dinucleotides were CpGs 1–4 and 9–16 (Fig. 2). Since
these differentially methylated CpGs may regulate the silencing of
the CXCR4 gene, these regions were subsequently analyzed in
primary tumors samples using Methylation-Specific PCR (MSP).
MSP analysis in breast tumor cell lines
CpG dinucleotides 1 to 4 and 9 to 16, which lie within a region
that is differentially methylated, were chosen for MSP analysis (as
described in material and methods) (Fig. 2). The MSP technique
was tested with DNA from the tumor cell lines to confirm if this
DNA region could be used to analyze the CXCR4 methylation
pattern in primary tumors (Fig. 3A). RT-PCR results from the cell
lines were then used to compare the pattern of gene expression to
the presence or absence of DNA methylation detected by the MSP
technique. The MDA-MB-435 breast tumor cell line showed a
methylated fragment in the CXCR4 CpG island, which correlated
with the lack of CXCR4 expression in this cell line. In contrast, the
PMC-42, MCF7 and MDA-MB-436 cell lines, which express
CXCR4, demonstrated only unmethylated fragments (Fig. 3A).
Therefore, the MSP results from the breast tumor cell lines
corroborated with both the RT-PCR and sequencing data.
MSP analysis in primary breast tumors
The MSP assay was subsequently used to analyze the
methylation of the CXCR4 gene in primary breast tumor samples.
For the methylated and unmethylated conditions, thirteen
representative tumor samples are shown (Fig. 3B). From all the
samples tested (69), only three contained both methylated and
unmethylated CpG dinucleotides. Based on this result, we
concluded that CXCR4 could be partially silenced, or the
mechanism of silencing could progress during the tumorigenesis
process (Fig. 3B). However, a lack of methylation of the CXCR4
gene was found in the majority of the samples with 46 out of the 69
samples (67%) not showing CpG methylation in the region
evaluated by MSP.
Correlations between the CXCR4 promoter methylation
status and clinicopathological data
Sato et al. (2005) [18] analyzed a DNA region comprised of
nucleotides from the 2173 to +11 positions in the CXCR4
promoter. This region was shown to contain 19 CpGs, which were
used to determine the methylation pattern of the CXCR4 gene and
correlates this pattern with CXCR4 gene silencing in human
pancreatic cancer cell lines. In this study, we used this region to
correlate the CpG island methylation pattern of the CXCR4 gene
with the clinical and pathological parameters shown in Table 1.
Unmethylated CXCR4 was not significantly associated with the age
of disease onset (p=0.466), estrogen receptor status (p=0.310),
HER2 expression (p=0.276), progesterone receptor status
(p=0.117), tumor recurrence (p=1.000) or histological type
(p=0.849). However, unmethylated CXCR4 did correlate with
the tumor stage (p,0.001), tumor size (p,0.001), histological
grade (p,0.001), SBR grade (p,0.001), lymph node status
(p=0.002), metastasis (p=0.026) and death (p=0.038). We also
found that the majority of the samples with more advanced stages
(II or III/IV) were unmethylated (82% and 94%, respectively).
Similar results were observed for the tumor size (pT3/T4=95%)
and SBR grade (III=95%). Additionally, samples that were
positive for lymph nodes had a higher percentage of unmethylated
CXCR4 (82%). We also correlated the methylation pattern of the
CXCR4 gene promoter with the methylation status of the ESR1
and CXCL12 genes, which had been previously studied by our
group [17]. Unmethylated CXCR4 was significantly associated
with methylated ESR1 and CXCL12 (p=0.006 and p=0.001,
respectively).
These results suggest that the CpG island methylation in the
CXCR4 gene may be an important prognostic factor for breast
cancer. To test this hypothesis, we analyzed all of the clinical and
clinicopathological data for prognostic value in a univariate
analysis for disease-free survival (DFS) and overall survival (OS)
using Kaplan-Meier Curves (p values were generated using the log
rank test). The tumors from patients with an unmethylated CXCR4
Figure 2. Bisulfite sequencing of the CXCR4 gene promoter in the breast cancer cell lines. The cell lines used are shown. The nineteen
dinucleotides are numbered in agreement with the sequence. The open circles represent the unmethylated dinucleotides while the gray to black
portion represents the percentage of methylation. On the right side methylation pattern are represented according to data of RT-PCR and the
absolute percentage value. The arrows below the CpG dinucleotides represent the MSP primers that were used.
doi:10.1371/journal.pone.0029461.g002
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tumors containing CXCR4 methylation for overall survival (OS)
(p=0.038) and disease-free survival (DFS) (p=0.009) (Fig. 4A and
B). To identify the impact of signaling between CXCL12 and
CXCR4, we generated the Kaplan-Meier curves with a combina-
tion of both genes. These data demonstrated that patients with
hypermethylated CXCL12 and unmethylated CXCR4 had a shorter
OS and DFS (p=0.045 and p=0.016, respectively) (Fig. 4C and
D). Thus, methylated CXCL12, which was previously studied as a
marker of poor patient prognosis [17], may be accompanied by a
process involving the unmethylated or hypomethylated CXCR4
gene promoter. While the mechanism behind these processes
remains to be identified, these results agree with the hypothesis
that tumoral cell dissemination may occur with the silencing or
absence of CXCL12 in the same cells over-expressing the CXCR4
protein.
Discussion
Breast cancer is the most common malignant tumor affecting
women worldwide. Metastasis is an important feature of malignant
tumors and has a major impact on the prognosis and therapeutic
decisions for patients. The metastatic process is multi-factorial,
non-random and exhibits organ selectivity. Lymph node metas-
tases are the most frequently occurring type of metastatic lesion
[20]. Chemokine receptors are defined by their ability to induce
the directional migration of cells toward a chemotactic cytokine
gradient, and the CXCR4 receptor is essential for development,
hematopoiesis, organogenesis and vascularization [21]. Muller et
al. demonstrated that CXCR4 is undetectable in normal
mammary gland tissue but is consistently expressed in human
breast cancer cells and metastases. The ligand of CXCR4,
CXCL12, is preferentially expressed in organs targeted by
metastases, such as the lungs, liver, bone marrow and lymph
nodes [13]. Additional reports have demonstrated that a high
CXCR4 expression pattern correlates with lymph node metastases
from invasive ductal breast cancer [15,16].
Recent emphasis has been placed on the critical role of
epigenetic changes, especially DNA methylation and histone
modifications, in human carcinogenesis. Epigenetic changes differ
from genetic changes as they occur at a higher frequency, are
reversible upon treatment with pharmacological agents and occur
at defined regions within genes [7]. The CXCR4 gene has been
shown to be epigenetically regulated in endometrial carcinoma
[22], melanoma [19], colonic carcinoma [23] and pancreatic
cancer [18]. In this study, we investigated the methylation status of
the 59 TSS region of the CXCR4 promoter in primary breast
tumor samples.
First, we evaluated the regulation of the CXCR4 gene by DNA
methylation in breast cancer cell lines. MDA-MB-435 demon-
strated a repression of CXCR4 gene expression, which was restored
after 5-aza-CdR treatment (Fig. 1A and 1B). This result agrees
with the data from pancreatic cancer cell lines [18]. Then, a
184 bp fragment of the CXCR4 promoter, which harbored the
TSS motif that contains 19 CpGs, was sequenced in breast cancer
cell lines. This region was differentially methylated according to
the CXCR4 expression levels (Fig. 2). The MSP technique was then
used to demonstrate that 46 of the 69 samples analyzed were not
methylated (67%). These data are novel for breast cancer since
only pancreatic primary carcinomas have previously been studied
for CXCR4 DNA methylation. In pancreatic cancer, CXCR4
methylation occurred in 46% of the tumors but did not display any
significant associations with common clinicopathological factors,
such as age, gender, stage or lymph node metastasis [18].
The importance of oncogene methylation in cancer is still
poorly understood. The inactivation of oncogenes confers a
selective disadvantage to tumor cells by threatening the survival of
the cell and negatively affecting carcinogenesis [24]. Muller et al.
[13] showed that CXCR4 gene expression is absent or down
regulated in normal breast cells, and this result was also confirmed
in other tumor cell types. Singh et al. (2004) observed that the
CXCR4 mRNA and protein levels were significantly higher in
prostate cancer cell lines (PC3 and LNCaP) compared to normal
prostate epithelial cells (PrEC) [25]. A similar finding was reported
by Meier et al. (2007) in neuroblastoma cell lines where invasive
cells lines (IGR-N91, SH-SY5Y) had high expression levels of
CXCR4, whereas a non-invasive neuroblastoma cell line (IGR
NB8) expressed low levels of the CXCR4 gene [26]. These data
suggest that mechanisms, likely including DNA methylation, exist
in normal cells to reduce the expression of CXCR4. Thus, cancer
progression could lead to the demethylation of the CXCR4
promoter to selectively favor tumor growth and cell migration.
Tumors with a poor prognosis in our study, such as stage III
(94%), tumor size T3/T4 (82%) or SBR III (95%), had
unmethylated CXCR4 (p,0.001). The demethylation of an
oncogene, such as CXCR4, could be involved in processes such
as cell migration and metastasis. Thus, the regulation of this gene
deserves attention for its involvement in disease progression.
Figure 3. MSP analysis in breast cancer cell lines and primary breast tumors. (A) Primer standardization for methylated and unmethylated
conditions in tumor cell lines. (B) MSP analysis of primary tumors. Thirteen samples are represented. MW, Molecular Weight; NC, Negative Control.
doi:10.1371/journal.pone.0029461.g003
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over-expression and patient outcome [27]. This group analyzed
the association of locally advanced breast cancer (stages IIB or III
of the TNM staging system) and CXCR4 expression after
neoadjuvant therapy. The survival was poor for patients whose
CXCR4 expression levels remained high following neoadjuvant
therapy [27].
Our study showed a statistical correlation between a positive
lymph node status and unmethylated CXCR4 (p=0.002). A
similar correlation was observed between unmethylated CXCR4
and the presence of metastases (86% of the samples were
unmethylated) (p=0.026) and non-survival (82% of the samples
were unmethylated) (p=0.038). These results showed a correla-
tion between a poor prognosis and an unmethylated CXCR4
promoter. Data discussing the expression of CXCR4 and the
association of the CXCR4 with metastasis in the literature are
somewhat controversial. Andre et al. (2006) found a correlation
between CXCR4 expression and liver metastases but no
correlation was found between the expression of the CXCR4
protein with various clinicopathological variables, such as age,
tumor grade, estrogen receptor status or HER2 expression [28].
Kang et al. (2005) reported an association between high CXCR4
protein levels and lymph node metastasis but not with distant
metastases [29]. Kato et al. (2003) examined the CXCR4 staining
patterns in focal and diffuse-type tumors and found no significant
differences in the pathological types, histological grades or
estrogen receptor statuses of the tumor types [14]. However, a
significant correlation was observed between the CXCR4 protein
level and the degree of lymphatic spread but not hematogenous
metastases [15]. Holm et al. (2007), opposed to Andre et al. (2006)
[28], found a significant correlation between a high CXCR4
protein expression level and a HER2-negative status [30].
Conversely, Woo et al. (2008) found a significant association
between a high nuclear expression of CXCR4 with the
occurrence of metastasis in the lymph nodes. According to this
study, tumors that were CXCR4+/lymph node+ were associated
with a negative ER and PR status [31]. Kang et al. (2005) found
no correlation between CXCR4 expression and overall survival
or disease-free survival of patients but found statistically
significant higher levels of CXCR4 protein in node-positive
tumors [29]. The expression of CXCR4 was also higher among
patients with distant metastases, but no significant correlation
between these factors was found [29].
The lack of correlation between CXCR4 protein expression and
a positive lymph node status or distant metastases was discussed by
Shim et al. (2006) [32]. They observed a high expression of
CXCR4 in primary tumors, whereas cytoplasmic expression of
this receptor was undetected in most secondary lymph nodes
tumors. The reduced expression of CXCR4 on the cell surface can
be justified by the high expression of the CXCL12 protein in the
lymph nodes [32] as CXCL12 stimulates the internalization and
subsequent lysosomal degradation of CXCR4.
Furthermore, we evaluated the correlation between unmethy-
lated CXCR4 and the hypermethylation of other genes strongly
associated with breast cancer. Our previous results with the same
Table 1. Clinicopathological features of 69 patients with
primary breast carcinomas and methylation status of CXCR4
gene.
Variables Samples (%)
CXCR4
Methylation p value
Yes (%) No (%)
Age
,45 9 (13) 2 (22) 7 (78) 0.466
$45 60 (87) 24 (40) 36 (60)
Stage
I 19 (27) 14 (74) 5 (26) ,0.001
II 33 (48) 6 (18) 27 (82)
III/IV 17 (25) 1 (6) 16 (94)
Tumour size
pT1 17 (25) 12 (71) 5 (29) ,0.001
pT2 35 (50) 7 (20) 28 (80)
pT3/pT4 17 (25) 3 (18) 14 (82)
SBR
I 19 (28) 14 (74) 5 (26) ,0.001
II 32 (46) 7 (22) 25 (78)
III 18 (26) 1 (5) 17 (95)
Lymph node status
Positive 33 (48) 6 (18) 27 (82) 0.002
Negative 35 (52) 19 (42) 16 (58)
Estrogen receptor (RE)
Positive 57 (84) 21 (37) 36 (63) 0.310
Negative 11 (16) 2 (18) 9 (82)
HER-2
Positive 19 (31) 4 (21) 15 (79) 0.276
Negative 43 (69) 15 (35) 28 (65)
Progesterone receptor
(PR)
Positive 46 (74) 16 (35) 30 (65) 0.117
Negative 16 (26) 2 (12) 14 (88)
ESR1 Methylation*
M 28 (41) 6 (21) 22 (79) 0.006
U 40 (59) 22 (55) 18 (45)
CXCL12 Methylation*
M 37 (54) 12 (32) 25 (73) 0.001
U 32 (46) 21 (67) 11 (33)
Metastasis
Positive 21 (30) 3 (14) 18 (86) 0.026
Negative 48 (70) 20 (42) 28 (58)
Death
Positive 17 (25) 3 (18) 14 (82) 0.038
Negative 50 (75) 23 (46) 27 (54)
Recurrence
Positive 10 (14) 3 (30) 7 (70) 1.000
Negative 59 (86) 20 (34) 39 (66)
Histogical type
Ductal Carcinoma Invasive 50 (72) 17 (34) 33 (66) 0.849
Lobular Carcinoma Invasive 19 (28) 6 (32) 13 (68)
Abbreviations: p, value from statistical analysis x
2 test and Fisher’s exact test;
M, methylated; U unmethylated; significant data are in bold.
*CXCL12 and ESR1 methylation data were used from a previous study published
by our group [17].
doi:10.1371/journal.pone.0029461.t001
Table 1. Cont.
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occurred at higher frequencies in patients with metastases and
death [17]. In this study, we evaluated whether unmethylated
CXCR4 with concurrent CXCL12 hypermethylation produced a
more aggressive disease phenotype. Tumors from patients with an
unmethylated CXCR4 gene had a significantly poorer OS and
DFS compared to patients with tumors containing methylated
CXCR4 (p=0.038 and p=0.009, respectively) (Fig. 4A and B).
However, Kaplan-Meier analysis demonstrated that patients with
unmethylated CXCR4 and methylated CXCL12 had shorter overall
and disease free survivals (p=0.045 and p=0.016, respectively)
(Fig. 4C and D). The molecular mechanisms facilitated by
CXCL12 and its partner, CXCR4, which result in the poor
prognosis for these patients remain obscure.
Previously, with the same patient cohort, we demonstrated that
ESR1 was inactivated by DNA hypermethylation, which resulted
in the loss of the receptor for the estrogen protein (ER) [17]. We
hypothesized that the decrease of estrogen would lead to all ER
target genes becoming susceptible to epigenetic silencing [33],
including CXCL12 [17] and the unmethylated CXCR4 promoter,
which would thus lead to a more aggressive disease.
The main limitation of our study was the small sample size.
However, even with the limited number of samples, we were able
to observe strong correlations between epigenetic changes in both
CXCR4 and CXCL12 and a poor prognosis. We believe that the
statistical differences found here underline the importance of
changes in the DNA methylation of chemokines and their
receptors in the process of tumor progression. These new
discoveries may provide a molecular prognostic factor for breast
cancer and may help to develop therapies that are more effective
for this type of cancer. Our results could also open new avenues for
a more efficient management of metastatic disease in breast
cancers.
In summary our data demonstrate for the first time that CXCR4
gene expression in primary breast tumors is regulated by DNA
methylation, and CXCR4 methylation associates with several
clinicopathological parameters. Loss of DNA methylation in the
promoter region of CXCR4 correlated with a more aggressive
disease in terms of tumor stage, tumor size, SBR grade,
5demonstrated that concurrent epigenetic changes of CXCR4
and its ligand, CXCL12, correlated with shorter disease-free and
overall survivals. We believe that our findings will be important for
Figure 4. Kaplan Meier curves for overall survival and disease-free survival according to the methylation status of CXCR4 and
CXCL12. CXCR4 methylation status and the correlation with (A) overall survival (OS) and (B) disease-free survival (DFS) are shown. CXCL12 methylation
status and association to CXCR4 methylation for (C) OS and (D) DFS are shown.
doi:10.1371/journal.pone.0029461.g004
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research is needed to unveil additional molecular mechanisms
associated with the metastatic process.
Materials and Methods
Cell lines
Breast tumor cell lines were obtained from the Ludwig Institute
for Cancer Research (Sa ˜o Paulo, Brazil). The following cell lines
were used: MDA-MB-436, MDA-MB-435, MCF7 and PMC-42.
The cell lines were cultured at 37uC in a humidified incubator
with 5% CO2 in RPMI 1640 medium containing 10% fetal bovine
serum supplemented with 0.2 mM glutamine and 40 mg/mL
gentamicin.
Patient samples
For the methylation analysis, frozen samples of breast tumors
(n=69) were obtained from breast cancer patients treated by
primary surgery at the Nossa Senhora das Grac ¸as Hospital,
Curitiba, PR, Brazil, with institutional approval. The study
included female patients with invasive breast tumors. All patients
gave informed consent for their tissue to be retained and analyzed
for research purposes. The ages of the patients ranged from 27 to
84 years (mean 57.8614.7). The histological types of the tumors
were either infiltrative ductal carcinoma (IDC) (n=51, 74%) or
infiltrative lobular carcinoma (ILC) (n=18, 26%). The lymph
node statuses of the patients were determined and included 51%
positive (n=35) and 49% negative (n=33) samples. The
histological grades of the tumors were determined according to
the modified Bloom-Richardson criteria. Of the patients analyzed,
28% were Grade I, 48% were Grade II and 24% were Grade III.
TNM staging was determined according to the World Health
Organization (WHO) classification [34]. The tumor samples were
the same samples used by Ramos et al. (2010) [17]. The patients’
clinicopathological data are shown in Table 1.
Ethics Statement. All patients gave their informed written
consent for their tissues to be retained and analyzed for research
purposes. All signed consent forms are in the custody of the
corresponding author. This study was approved by the National
Committee of Ethics in Research with the process number
25000.007020/2003-93. Institutional approval was granted by the
Ethics Committee of Human Beings Research from the Federal
University of Parana (UFPR) with the register number 7220-251/
2003 (20/02/2003).
Immunohistochemistry
Immunohistochemical (IHC) staining of the tumor samples was
evaluated and scored by two pathologists who were also
responsible for generating of the clinicopathological data. The
estrogen receptor (ER) and progesterone receptor (PR) were
detected using the specific monoclonal antibodies 1D5 and PgR
636 (DAKO), respectively. The cut-off values for the ER and PR
statuses were 10% positively stained cells. The HER2 analysis was
performed using the HercepTest
TM (DAKO CYTOMATION
code K5204). When a result of +2 positive was obtained, an in situ
fluorescent hybridization (FISH) assay was performed to confirm
the result. Other clinicopathological data (e.g., tumor size, local
recurrence, metastasis and death) are summarized in Table 1.
RNA extraction and reverse transcription
Total RNA was isolated using the TRIzolH Reagent (Invitrogen)
according to the manufacturer’s protocol. Reverse transcription
reactions were performed using 500 ng of DNA-free RNA, an oligo
(dT)12–18 primer and Superscript II Reverse Transcriptase (Gibco,
BRL). PCR was performed using CXCR4-specific primers and
GAPDH-specific primers as a positive control (Table 2). The PCR
was performed in a 20 ml volume containing 16 PCR buffer
(Invitrogen), 1.5 mM of MgCl2 (Invitrogen), 200 mM dNTPs,
0.3 mM of each primer and 1 U of Platinum Taq (Invitrogen).
The PCR conditions were as follows: 95uC for 10 min, 94uC for
45 s, the appropriate annealing temperature for 45 s, 72uC for
1 min and a final extension of 72uC for 5 min. PCR products were
resolved on 1% agarose gels and stained with ethidium bromide.
5-aza-29-deoxycytidine (5-aza-CdR) treatment
The MDA-MB-435 cell line were plated (1610
6 cells/ml) and
treated for 7 days with 1 mM 5-aza-CdR (Sigma Aldrich, Geisenhein,
Germany) or left untreated for an equivalent time. The media was
changed daily, and no significant cell death was observed. After
treatment for 7 days, total RNA was isolated. The expression of
CXCR4 in breast tumor cells was analyzed using semi-quantitative RT-
PCR with GAPDH as an internal control. The PCR products were
resolved on a 1% agarose gel and stained with ethidium bromide.
Table 2. Sequence of the primers used for RT-PCR, nested-PCR and MSP.
Application and
specificity Forward primer (59-39) Reverse primer (59-39)
Product
size (bp)
Annealing
Temperature (6C)
RT-PCR
CXCR4 CAGCAGGTAGCAAAGTGA AGCGTGATGACAAAGAGG 389 58
GAPDH CTGCACCACCAACTGCTTA CATGACGGCAGGTCAGGTC 296 63
nested-PCR
CXCR4 AGGAAATGTTTTTGGGAGGTTTTG TTTTGATTTGAATGTGATTAGGG - 50, 52, 54
CXCR4 nested AGTAGGGTTTTTTGGGTTTTTTAAGT TTGGTTGTTTGATTTTAAAGATTGG 184 52, 54, 56
SATR-1 GTTATATTATTTTTTGTTTTTTTG ACATTTCCTTATAATATTATTCC - 48, 50, 52
SATR-1 nested TATAGTGGTGGTGTATATTTG CACCTAACCTATAATATTTCTTC 690 52, 54, 56
MSP-PCR
CXCR4 – M CGCGTATTTTTTCGTTTCG AATCGCCGCATACGCAGC 99 61
CXCR4 – U AAGTTGTGTATTTTTTTGTTTTG ACATACACAACACAAACCTCAC 110 50
Abbreviations: M, specific for methylated condition; U, specific for unmethylated condition.
doi:10.1371/journal.pone.0029461.t002
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Genomic DNAwasisolatedfrom the MDA-MB-436,MDA-MB-
435, MCF7 and PMC-42 breast cancer cell lines or frozen tumor
samples using a phenol/chloroform extraction [35]. The DNA was
then subjected to sodium bisulfite treatment using an EpiTectH
Bisulfite Kit (Qiagen) according to the manufacturer’s instructions.
CXCR4 CpG island methylation analysis
The DNA region located between positions 2173 and +11 from
the 59-flanking region of the CXCR4 gene, which contained a
184 bp fragment with 19 CpG dinucleotides, was examined. The
DNA fragment was amplified from bisulfite-treated DNA of
breast tumor cell lines and tumor samples using a nested-
PCR amplification protocol. We designed primers using the
Methprimer program (http://www.urogene.org/Methprimer/index1.
html). Briefly, two sets of primers were used for the nested PCR
reactions at their appropriate annealing temperatures. The primer
sequences are shown in Table 2. The amplified products were
purified using a Qiaquick Gel Extraction Kit (Qiagen) and cloned
into the pCR2.1 cloning vector (Invitrogen). Eight clones were
sequenced for each cell line using the universal or reverse primers.
The DNA sequencing reactions were performed using Big Dye
Terminator technology on ABI 377 sequencer (Applied Biosystems)
according to the manufacturer’s instruction. One hundred percent
methylation was obtained if a methylated cytosine in the CpG
dinucleotide was present in all eight sequenced clones. The
methylation percentage for each tumor cell line (global methylation
pattern) was calculated by dividing the number of methylated CpG
dinucleotides by the total number of CpGs analyzed.
Methylation-specific PCR (MSP)
After sequencing a 184 bp fragment from the bisulfite treated
DNA, we identified the differentially methylated CpG dinucleo-
tides in samples that expressed and did not express the CXCR4
gene. We designed primers for MSP according to the method
described by Herman et al. [36]. The genomic DNA (gDNA) from
the primary breast tumors was treated with sodium bisulfite and
amplified with the CXCR4 primers specific for the methylated (M)
and unmethylated (U) DNA (Table 2).
MSP reactions were performed with 1 ml of bisulfite-modified
DNA, 16 PCR buffer (Invitrogen), 1.5 mM of MgCl2, 200 mM
dNTPs, 0.3 mM of each primer and 1 U of Platinum Taq
(Invitrogen). The PCR protocol conditions were as follows: 95uC
for 10 min; 38 cycles of 94uC for 45 s, the appropriate annealing
temperature for 30 s and 72uC for 45 s, followed by a final
extension of 72uC for 5 min. The DNA conversion efficiency was
confirmed using a nested-PCR reaction with a set of primers for a
previously described satellite region [37]. This reaction was used as
a control for the bisulfite modification quality. The PCR reaction,
nested PCR and temperature conditions are all described in
Table 2. The amplification products were separated on 2%
agarose gels and stained with ethidium bromide.
Statistical analyses
The statistical analyses were performed using the SPSS program
(version 16.0, SPSS Inc., Chicago, Illinois, USA). Associations
between the specific histopathological and clinical parameters
were analyzed using a chi-squared test and Fisher’s exact test. The
survival function was calculated from the time of disease onset to
the occurrence of death. The survival data were censored on April
30
th, 2010, the final date that the survival data were correlated
with the death registry. This resulted in a mean survival of 103
months after the onset of the disease. The Kaplan-Meier estimates
were presented for the survival functions, and the differences in
survival were analyzed using the log rank test. Cox proportional
hazards regression analysis was used to estimate the hazards ratio
(HR) and 95% confidence intervals (95% CI) for the overall
survival and disease-free survival as defined by local recurrence or
distant recurrence, whichever occurred first. Statistical significance
was assumed for a p,0.05.
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